Stock IMM IMMUTEP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Immutep Limited

Equities

IMM

AU000000IMM6

Market Closed - Australian S.E.
Other stock markets
 02:10:21 2024-04-16 am EDT 		5-day change 1st Jan Change
0.36 AUD 0.00% Intraday chart for Immutep Limited -11.11% +4.35%
Mar. 25 Encouraging results for Immutep's cancer therapies FI
Mar. 05 Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Immutep : Corporate Presentation
PU
Encouraging results for Immutep's cancer therapies
FI
Ladenburg Thalmann - Next Is Dose Optimization for BC Program; Reiterate Buy, $8.30 PT (Analyst: Ahu Demir, PhD)
PU
Wilsons - Dose it higher? Now an option; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)
PU
Immutep Announces First Clinical Data from 90mg Dosing of Efti
AQ
Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti
CI
Immutep Posts 59% Rise in H1 FY24 Revenue, Narrows Net Loss
MT
Immutep Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Immutep Quarterly Activities Report Q2 FY24
AQ
Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer
CI
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
AQ
Immutep Doses First Patient in Cancer Trial
MT
Immutep Limited Announces Change of Registered Office Address
CI
Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
CI
Immutep : Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
PU
Immutep Receives $1.7 Million Research, Development Tax Incentive From French Government
MT
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
AQ
Immutep Secures 1.6 Million Euro French R&D Tax Rebate for 2022
MT
Immutep Says More Sites Added to Insight-003 Phase 1 Trial for Lung Cancer Treatment
MT
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMM Stock
  4. News Immutep Limited